Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels
- PMID: 19906261
- DOI: 10.1111/j.1749-6632.2009.05066.x
Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels
Erratum in
- Ann N Y Acad Sci. 2010 Feb;1188:231. Rohrer, Alex [corrected to Roher, Alex]
Abstract
Alzheimer's disease (AD) is a debilitating neurodegenerative disorder with incidence expected to increase four-fold over the next decade. Extensive research efforts are focused upon identifying new treatments, and early diagnosis is considered key to successful intervention. Although imaging and cerebrospinal fluid biomarkers have shown promise in identifying patients in very early stages of the disease, more noninvasive cost-effective tools have remained elusive. Recent studies have reported that an 18-analyte multiplexed plasma panel can differentiate AD from controls suggesting plasma-based screening tools for early AD diagnosis exists. The current study tested the reproducibility of a subset of the original 18-analyte panel using a bead-based multiplex technology. Preliminary results suggest diagnostic accuracy using the subset was 61%. Multivariate analysis of an 89-analyte multivariate panel yielded a diagnostic accuracy of 70% suggesting a plasma-based AD signature that may be a useful screening tool.
Similar articles
-
Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease.Electrophoresis. 2002 Jul;23(14):2247-51. doi: 10.1002/1522-2683(200207)23:14<2247::AID-ELPS2247>3.0.CO;2-M. Electrophoresis. 2002. PMID: 12210229
-
Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease.Ann Neurol. 2007 Feb;61(2):120-9. doi: 10.1002/ana.21038. Ann Neurol. 2007. PMID: 17167789
-
Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease.Neurobiol Aging. 2008 Jul;29(7):961-8. doi: 10.1016/j.neurobiolaging.2007.01.011. Epub 2007 Feb 23. Neurobiol Aging. 2008. PMID: 17321007
-
Alzheimer's disease cerebrospinal fluid biomarker discovery: a proteomics approach.Curr Opin Mol Ther. 2005 Dec;7(6):557-64. Curr Opin Mol Ther. 2005. PMID: 16372405 Review.
-
Biomarkers for Alzheimer's disease.Expert Rev Neurother. 2007 Aug;7(8):1021-8. doi: 10.1586/14737175.7.8.1021. Expert Rev Neurother. 2007. PMID: 17678497 Review.
Cited by
-
Plasma Brain-Derived Neurotropic Factor Levels Are Associated with Aging and Smoking But Not with Future Dementia in the Rotterdam Study.J Alzheimers Dis. 2021;80(3):1139-1149. doi: 10.3233/JAD-200371. J Alzheimers Dis. 2021. PMID: 33646145 Free PMC article.
-
Peripheral Biomarkers for Early Detection of Alzheimer's and Parkinson's Diseases.Mol Neurobiol. 2019 Mar;56(3):2256-2277. doi: 10.1007/s12035-018-1151-4. Epub 2018 Jul 14. Mol Neurobiol. 2019. PMID: 30008073 Review.
-
Blood-Derived Plasma Protein Biomarkers for Alzheimer's Disease in Han Chinese.Front Aging Neurosci. 2018 Dec 17;10:414. doi: 10.3389/fnagi.2018.00414. eCollection 2018. Front Aging Neurosci. 2018. PMID: 30618720 Free PMC article.
-
Blood-based molecular biomarkers for Alzheimer's disease.Mol Brain. 2019 Mar 28;12(1):26. doi: 10.1186/s13041-019-0448-1. Mol Brain. 2019. PMID: 30922367 Free PMC article. Review.
-
Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration.Neurology. 2017 Nov 21;89(21):2167-2175. doi: 10.1212/WNL.0000000000004667. Epub 2017 Oct 25. Neurology. 2017. PMID: 29070659 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical